1 2 4 7 a r t I C l e S Schizophrenia affects up to 1% of the population, in many cases causing life-long disability 1 . Antipsychotic drugs, including both typical (e.g., haloperidol) and atypical (e.g., clozapine), were serendipitously discovered in the mid-twentieth century 2 . Although chronic administration of these agents produces significant reduction or even complete remission of psychotic symptoms such as hallucinations and delusions 3,4 , the majority of schizophrenia patients have cognitive deficits, which often do not improve upon antipsychotic drug treatment; some patients even deteriorate [5] [6] [7] [8] . This clinical observation is supported by previous reports that long-term antipsychotic medication leads to a decline of cognitive abilities in rodent models 9,10 . Cognitive impairment in schizophrenia patients is selective and includes impairment in attention, executive function and working memory. Given that these deficits in cognitive processes account for a significant proportion of psychosocial disabilities in schizophrenia patients 11, 12 , it is notable that no study so far has determined the basic molecular mechanism by which chronic antipsychotic drug treatment may lead to a negative effect on cognitive function.
Schizophrenia affects up to 1% of the population, in many cases causing life-long disability 1 . Antipsychotic drugs, including both typical (e.g., haloperidol) and atypical (e.g., clozapine), were serendipitously discovered in the mid-twentieth century 2 . Although chronic administration of these agents produces significant reduction or even complete remission of psychotic symptoms such as hallucinations and delusions 3, 4 , the majority of schizophrenia patients have cognitive deficits, which often do not improve upon antipsychotic drug treatment; some patients even deteriorate [5] [6] [7] [8] . This clinical observation is supported by previous reports that long-term antipsychotic medication leads to a decline of cognitive abilities in rodent models 9, 10 . Cognitive impairment in schizophrenia patients is selective and includes impairment in attention, executive function and working memory. Given that these deficits in cognitive processes account for a significant proportion of psychosocial disabilities in schizophrenia patients 11, 12 , it is notable that no study so far has determined the basic molecular mechanism by which chronic antipsychotic drug treatment may lead to a negative effect on cognitive function.
The epigenetic removal of acetyl groups from histone tails by histone deacetylases (HDACs) promotes a compact chromatin structure that represses gene transcription 13 . Endogenous HDAC2 activity plays a critical role in cognitive performance and appears to generally restrain both structural and functional synaptic plasticity 14, 15 . We have previously showed that chronic treatment with the atypical antipsychotic drug clozapine leads toward a selective augmentation of Hdac2 transcription in mouse frontal cortex 16, 17 , a brain region that is important in cognition and perception and that has been implicated in schizophrenia and antipsychotic drug responses [18] [19] [20] [21] . It remains unknown, however, whether this upregulation of HDAC2 expression is involved in either the therapeutic or negative side effects of atypical antipsychotic medications. Furthermore, the neural substrates and upstream signaling leading to such upregulation of Hdac2 transcription have not been resolved.
In this study, we show that augmentation of HDAC2 expression upon chronic atypical antipsychotic treatment maladaptively affects cortical synaptic remodeling and cognitive processes through a signaling mechanism that involves serotonin 5-HT 2A -receptor-dependent upregulation of NF-κB activity.
2 4 8
VOLUME 20 | NUMBER 9 | SEPTEMBER 2017 nature neurOSCIenCe a r t I C l e S RESULTS Chronic atypical antipsychotics upregulate HDAC2 in frontal cortex pyramidal neurons We had previously shown that chronic treatment with the atypical antipsychotic drug clozapine induces upregulation of Hdac2 transcription in mouse frontal cortex 16 . We found here similar effects after chronic treatment with the atypical antipsychotic and antipsychoticlike drugs clozapine, risperidone, quetiapine, sulpiride and volinanserin (M100907) but not with the typical antipsychotic haloperidol (Fig. 1a) . Hdac1 and Hdac8 mRNAs were unaffected after treatment with either atypical or typical antipsychotics (Fig. 1b,c) . Expression of Hdac1, Hdac2 and Hdac8 mRNA was decreased after chronic treatment with the antidepressant drug fluoxetine (Fig. 1a-c) .
Multiple lines of evidence implicate disturbances in cortical pyramidal neurons [22] [23] [24] and cortical parvalbumin (PV) + GABAergic interneurons 25 as being potentially involved in core psychotic and cognitive symptoms in schizophrenia patients. We used immunohistochemical markers to determine whether either of these neuronal populations showed upregulation of HDAC2 expression after chronic treatment with antipsychotic medications. Consistent with previous studies 15 , HDAC2 was ubiquitously expressed throughout the brain and was localized primarily within the cell nucleus (Fig. 1d,e and Supplementary Fig. 1a,b) . Notably, chronic treatment with clozapine and risperidone, but not with haloperidol, induced upregulation of HDAC2 in CaMKIIα + cortical pyramidal neurons (Fig. 1d,f and Supplementary Fig. 1a ) but not in PV + cortical GABAergic interneurons (Fig. 1e,g and Supplementary Fig. 1b ). This effect of chronic atypical antipsychotic drug treatment did not occur in CaMKIIα + hippocampal pyramidal neurons ( Supplementary Fig. 2a,b) and was absent after subchronic atypical antipsychotic drug treatment ( Supplementary Fig. 2c,d ).
Upregulation of cortical HDAC2 upon chronic clozapine treatment disrupts synaptic remodeling and cognition To evaluate the consequences of upregulation of HDAC2 in cortical pyramidal neurons by chronic treatment with atypical antipsychotic drugs in mice, we used a genetic strategy to selectively suppress HDAC2 function in CaMKIIα + glutamatergic neurons. We crossed loxP-flanked HDAC2 (Hdac2 loxP/loxP ) mice, which contain loxP sites upstream of exon 2 and downstream from exon 4 in the mouse Hdac2 gene-a mutation that allows us to delete a portion of the oligomerization domain as well as residues in the catalytic domain required for enzymatic activity 26 -with a second line of mice expressing Cre recombinase under the control of the CaMKIIα promoter (Fig. 1h) . We validated the predicted pattern of deletion of HDAC2 in CaMKIIα + pyramidal neurons but not in PV + GABAergic interneurons (Fig. 1i-m and Supplementary Fig. 3a-c) . We also found that the level of expression of other Hdac tested was unaffected in Hdac2 loxP/loxP : CaMKIIα-Cre mice (Hdac2-cKO) as compared to control littermates ( Supplementary Fig. 3d ), indicating an absence of compensatory events after deletion of HDAC2.
We next sought to determine what influence the lack of forebrain HDAC2 function would have on the potential effects induced by chronic treatment with atypical antipsychotic drugs on cortical pyramidal synaptic remodeling and behavior. Since it was previously shown that HDAC2 negatively regulates synaptic plasticity and cognition 15 , we hypothesized that upregulation of HDAC2 activity by chronic atypical antipsychotic drug treatment might have a detrimental impact on genes associated with dendritic structural remodeling and behavioral plasticity. To test this possibility, we performed poly(A) + RNA sequencing in frontal cortex samples from Hdac2-cKO mice and from control littermates treated chronically with either clozapine or vehicle. Broadly, we identified fewer differentially expressed genes in the frontal cortex of control animals that had received chronic clozapine treatment versus vehicle in comparison with the transcriptional profiles obtained in the frontal cortex of Hdac2-cKO mice that had received chronic clozapine treatment versus vehicle ( Fig. 1n and Supplementary Table 1) . Further gene ontology analysis indicated that substantial repression for several signaling pathways associated with cell morphogenesis, neuron projection and synapse structure occurred in control mice after chronic clozapine treatment (Supplementary Fig. 3e) . Notably, the number of differentially expressed genes associated with pathways involved in dendritic growth and neurogenesis was markedly enriched in the frontal cortex of Hdac2-cKO mice treated chronically with clozapine compared to chronic vehicle (Supplementary Fig. 3e ). These results support the notion that forebrain HDAC2 function leads to downregulation of synaptic formation and plasticity gene networks upon chronic clozapine treatment.
Dendritic spines are critical structural and functional units with important roles in cognitive processes 22 . To evaluate the structural consequences of HDAC2-dependent repression of these genes observed after long-lasting exposure to atypical antipsychotic drugs, we measured the effect of chronic clozapine treatment on dendritic spine density in CaMKIIα + cortical pyramidal neurons in Hdac2-cKO mice and controls. We targeted pyramidal neurons from frontal cortex of adult mice through the injection of adeno-associated virus (AAV8) bearing enhanced yellow fluorescent protein (eYFP) under the control of the CaMKIIα promoter (Supplementary Fig. 4a ). In slices prepared 3 weeks after injection, this configuration resulted in robust overexpression of eYFP in frontal cortex CaMKIIα + , but not PV + , neurons ( Supplementary Fig. 4b-d) , enabling explicit discrimination of single pyramidal cells and their dendritic spines. Notably, chronic treatment with clozapine selectively reduced the density of mature mushroom spines in CaMKIIα + frontal cortex neurons but not that of stubby or immature thin spines or total spine density ( Fig. 2a-e) . This synaptic remodeling event required the expression and function of HDAC2 in cortical pyramidal neurons, as the effect of chronic clozapine treatment on spine structure was absent in the frontal cortex of Hdac2-cKO mice (Fig. 2a-e) . The pattern of immunoreactivity against synaptophysin, which is specifically localized in presynaptic terminals of active synapses 15 , was similar in the frontal cortex of mice stereotaxically injected with AAV-eYFP compared to those given mock injections ( Supplementary Fig. 4e,f) . This indicates the absence of effects of AAV8 infection itself on density of functional synapses. Together, these observations suggest that gain of HDAC2 function upon long-lasting treatment with atypical antipsychotic drugs might impact their antipsychotic-related behavioral profiles.
To test this possibility, we examined cognitive capacities following chronic atypical antipsychotic drug treatment in Hdac2-cKO mice and controls. We found that a novel-object recognition test as a measure of cognitive performance (Supplementary Fig. 5a ) was significantly disrupted upon chronic ( Fig. 2f and Supplementary Fig. 5b ) but not subchronic ( Fig. 2h and Supplementary Fig. 5c ) clozapine treatment in control mice. This effect was not observed in Hdac2-cKO littermates ( Fig. 2g,i ; see also Supplementary Fig. 5d for absence of effect of chronic clozapine treatment on novel-object recognition test in heterozygous Hdac2 loxP/+ :CaMKIIα-Cre mice compared to controls). Similar findings were observed using water-finding ( Fig. 2j) and Y-maze (Fig. 2k) tests as behavior models of latent learning and short-term spatial recognition memory, respectively. This phenomenon prompted us to explore the signaling mechanisma r t I C l e S (l,m) Western blots showed decreased HDAC2 protein levels in the frontal cortex, but not cerebellum, of Hdac2-cKO compared to control littermates (n = 4-6 mice per experimental condition). Representative immunoblots are shown (m). (n) Comparative heat maps displaying genes significantly regulated (false discovery rate of 0.05 and fold change (log 2 ) of at least 0.02) by chronic clozapine treatment in either Hdac2-cKO mice or control littermates (n = 3 libraries per treatment per genotype). For data visualization purpose of the heat map, rlog-transformed data from the DESeq2 package were then scaled with a maximum value of 1 and a minimum value of -1 for each gene. Sidebar shows genes significantly regulated by chronic clozapine treatment in Hdac2-cKO (cyan) or control (yellow) mice or significantly regulated by chronic clozapine treatment in both Hdac2-cKO and control mice (red). Mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant. One-way ANOVA with Bonferroni's post hoc test (a: P = 0.02, F 7,48 = 1.22; b: P < 0.001, F 7,95 = 1.96; c: P < 0.001, F 7,44 = 1.89; f: P < 0.001, F 3, 224 = 5.36; g: P > 0.05, F 3, 108 = 0.35). Two-way ANOVA with Bonferroni's post hoc test (k: P = 0.0014, F 1,60 = 11.29). Two-tailed unpaired t test (l: cortex: P = 0.036, t 10 = 2.41; cerebellum: P = 0.76, t 6 = 0.31); nuclei were stained in blue with DAPI (d,e,i,j). Scale bars, 20 µm (d,e,i,j).
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VOLUME 20 | NUMBER 9 | SEPTEMBER 2017 nature neurOSCIenCe a r t I C l e S through which chronic antipsychotic drug treatment modulates cortical pyramidal HDAC2 expression, as well as direct effects of this pathway on synaptic structural elements and behavioral phenotypes that parallel schizophrenia.
Chronic clozapine treatment augments binding of NF-kB to the Hdac2 promoter Antipsychotic drugs all present a relatively high affinity for the 5-HT 2A receptor 3 ( Supplementary Fig. 6a ), and forebrain 5-HT 2A receptors have been involved in both beneficial 27, 28 and adverse 29, 30 effects of antipsychotic medications. Our previous findings, obtained after microarray studies followed by high-throughput quantitative realtime PCR assays, showed that specific 5-HT 2A -receptor-dependent signaling pathways lead to induction of expression of genes that act as transcription factors or indirectly modulate transcription in numerous tissues, including the CNS 18, 31 . This motivated us to screen the Hdac2 promoter for potential binding sites of transcriptional regulators. Using transcription factor binding databases 32 , we found a potential recognition element for NF-κB at the promoter region of the Hdac2 gene (Fig. 3a) . NF-κB is a family of dimeric transcription factors best studied for its involvement in inflammation and immune responses and that has more recently been shown to regulate synaptic plasticity and brain function 33 . Previous studies have indicated that p65, one of the prototypical NF-κB subunits, is selectively located at synapses and involved in regulating neuropsychological processes related to cocaine addiction 34 and depression 35 .
Based on this knowledge, we used a series of chromatin immunoprecipitation assays with an anti-p65 antibody in the mouse frontal cortex at different regions across the Hdac2 gene (Fig. 3b) . p65 binding was enriched at the Hdac2 promoter region located −454 to −299 base pairs upstream of the transcription start site (Fig. 3c) , a region that contains the predicted NF-κB binding site (Fig. 3a,b) , whereas we detected no binding at other positions along the Hdac2 gene (Fig. 3c) . The capacity of NF-κB to interact physically with a DNA fragment that corresponds with a putative NF-κB binding site within the promoter of the mouse Hdac2 gene was validated by fluorescence anisotropy assay ( Fig. 3d and Supplementary Fig. 6b,c) . We built a homology model of the NF-κB heteromer (p65-p50) bound to the Hdac2 promoter site that was consistent with our experimental results (Fig. 3e) . . Two-tailed paired t test (m: control versus untreated schizophrenics: P = 0.15, t 9 = 1.5, control versus treated schizophrenics: P = 0.54, t 9 = 0.63; n: control versus untreated schizophrenics: P = 0.54, t 9 = 0.62, control versus treated schizophrenics: P = 0.02, t 9 = 2.61). Two-way ANOVA with Bonferroni's post hoc test (f: P = 0.03, F 1,9 = 6.24; h: P = 0.94, F 1,17 = 0.004; i: P = 0.03, F 1,18 = 5.02). The α value was corrected for multiple independent null hypotheses using the Holm's sequentially Bonferroni method (c,g). Box plots in k-n present, in ascending order, minimum sample value, first quartile, median, third quartile and maximum sample value.
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We next evaluated the effect of chronic treatment with clozapine on NF-κB (p65) binding to the Hdac2 promoter in mouse frontal cortex. Notably, chronic clozapine treatment significantly increased NF-κB (p65) binding to the Hdac2 promoter (Fig. 3f) . This event did not occur in the frontal cortex of 5-HT 2A -null mutant (5HT2A-KO) mice ( Fig. 3f ; see also Supplementary Fig. 7a ,b for absence of effect of chronic atypical antipsychotic drug treatment on HDAC2 immunoreactivity in CaMKIIα + cortical pyramidal neurons of 5HT2A-KO mice). Together, these results suggest that 5-HT 2A -receptor-regulated pathways on cortical neurons modulate transcription of Hdac2 via a signaling mechanism that involves alterations in NF-κB function.
Chronic clozapine treatment augments NF-kB function via serotonin 5-HT 2A -receptor-dependent downregulation of IkBa To gain insight into the ability of chronic treatment with clozapine to enhance NF-κB (p65) binding to the promoter region of the Hdac2 gene, we measured mRNA expression of genes previously shown to function as fundamental modulators of the NF-κB pathway 33 . We found that chronic clozapine significantly decreased IκBα (also known as Nfkbia) mRNA in mouse frontal cortex ( Fig. 3g) , whereas this treatment did not affect expression of other genes involved in NF-κB-dependent signaling (Fig. 3g) . We next evaluated the effect of chronic clozapine on IκBα protein expression in mouse frontal cortex. Expression of IκBα, but not IκBβ, p65 or p50 (p105), was diminished upon chronic clozapine treatment as compared to vehicletreated mice, an effect that was not observed in 5HT2A-KO littermates ( To study the relevance of the effects observed in mice, we examined IκBα and p65 protein levels in postmortem frontal cortex of human subjects with schizophrenia untreated or treated with atypical antipsychotics and from individually matched controls (see Supplementary  Tables 2 and 3 for demographic information). Equivalent to the lower IκBα expression found in mouse frontal cortex after chronic treatment with clozapine, we observed decreased expression of IκBα but not p65 in the frontal cortex of humans with schizophrenia treated with atypical antipsychotics but not in the untreated group ( Fig. 3m-o) . The trend for reduced IκBα mRNA levels was also evident in postmortem frontal cortex of medicated schizophrenic subjects (Fig. 3k,l) .
To directly interrogate the functional relevance of these findings in mice and humans, and given that NF-κB is retained in the cytoplasm through its interaction with inhibitory IκB proteins, including IκBα 33 , we tested whether chronic antipsychotic drug treatment affects subcellular localization of NF-κB (p65) in frontal cortex pyramidal neurons. Consistent with previous studies 34 , NF-κB (p65) localization was most intense cytoplasmically in mouse cortical neurons (Fig. 4a) . Notably, chronic clozapine treatment selectively increased the nuclear/ cytoplasmic ratio of NF-κB (p65) in CaMKIIα + , but not PV + , frontal cortex neurons of wild-type mice ( Fig. 4a-e and Supplementary  Fig. 8a ). This trafficking event after chronic clozapine treatment was not observed in the frontal cortex of 5HT2A-KO mice (Fig. 4a,b) .
To further investigate the effect of chronic atypical antipsychotic drugs on the intracellular translocation of NF-κB, we performed immunocytochemistry assays in nuclear preparations from postmortem frontal cortex of schizophrenic humans and individually matched controls. We used anti-NeuN antibody, whose antigen is a specific marker for neuronal nuclei, to selectively separate neuronal from nonneuronal nuclei in postmortem human brain samples. Notably, consistent with our findings in mice ( Fig. 4a-e) , we observed a dramatic and selective augmentation in the nuclear accumulation of NF-κB (p65) within neuronal nuclei of frontal cortex samples from treated, but not untreated, humans with schizophrenia ( Fig. 4f,g ). This functional difference in subcellular distribution of NF-κB (p65) did not occur in non-neuronal frontal cortex nuclei of subjects with schizophrenia treated with atypical antipsychotics (Fig. 4f,h ). Similar findings were observed in immunoblot assays with antibodies against p65 in nuclear fractions of frontal cortex from treated, but not from untreated, schizophrenic subjects (Fig. 4i,j and Supplementary Fig. 8b ). These findings, along with the absence of changes in p65 expression in the frontal cortex of untreated schizophrenic subjects ( Fig. 3m-o) , suggest that alterations in nuclear translocation of NF-κB (p65) represent a consequence of continuous exposure to antipsychotic medications rather than a biochemical marker of schizophrenia in postmortem human brain.
5-HT 2A -receptor-dependent downregulation of IkBa upon chronic clozapine treatment via MAPK-ERK
We next focused our attention onto the downstream signaling events that mediate downregulation of IκBα expression after chronic clozapine treatment via 5-HT 2A receptors. As expected based on previous reports 18 , we found an induction of IκBα transcription in the frontal cortex of wild-type mice, but not 5HT2A-KO mice, intraperitoneally injected with the 5-HT 2A receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; Fig. 5a ). Similar effects were observed in mice injected with the serotonin precursor 5-hydroxytryptophan (5-HTP; Fig. 5b ). The mitogen-activated protein kinase (MAPK) pathway that leads to the activation of extracellular signal-regulated kinases (ERK1/2) has been linked to neuronal transcriptional events and might also regulate synaptic targets to control plasticity 36 We next examined whether this pathway is likewise affected by chronic treatment with antipsychotic drugs. As shown (Fig. 3g) , chronic clozapine treatment downregulated IκBα mRNA expression in mouse frontal cortex (Fig. 5d) . We also found that chronic clozapine treatment eliminated the induction of IκBα transcription upon activation of the 5-HT 2A receptor in the mouse frontal cortex (Fig. 5d) . We then demonstrated that absence of 5-HT 2A -receptordependent signaling altered the effect of chronic clozapine treatment on phosphorylated ERK levels in the mouse frontal cortex (Fig. 5e-g ). Notably, analysis of [ 3 H]ketanserin binding revealed a marked decrease in frontal cortex 5-HT 2A -receptor density only after chronic treatment with those atypical antipsychotic and antipsychotic-like drugs that augment Hdac2 expression but not with haloperidol (Figs. 1a and 5h and Supplementary Fig. 9g ). It has been suggested that the p65 subunit of NF-κB interacts with HDAC2 as part of the same protein complex to negatively regulate gene transcription [37] [38] [39] . Our data show that immunoprecipitation with anti-p65 antibodies in mouse frontal cortex did not result in co-immunoprecipitation of anti-HDAC2 immunoreactivity ( Supplementary Fig. 10a,b) . Together, these data suggest that chronic atypical antipsychotic drug treatment led to elevations in Hdac2 promoter activity within the frontal cortex through a linear signaling pathway that involves 5-HT 2A -receptordependent downregulation of IκBα expression via hypophosphorylation of ERK1/2.a r t I C l e S Inhibition of frontal cortex NF-kB function prevents the effects of chronic clozapine treatment on HDAC2 expression and cognitive deficits To corroborate the functional significance of changes in frontal cortex NF-κB-dependent transcriptional activity on HDAC2 expression upon chronic clozapine treatment, we next tested the effects of AAV-mediated gene transfer of a dominant-negative IκBα (IκBα-S32A-S36A; dn-IκBα), which is resistant to proteasome degradation and therefore constitutively inhibits NF-κB function 40 . Using a previously described nine-amino-acid p2A motif for co-expression of two proteins from a single promoter 41 , we separated Flag-dn-IκBα from eYFP and injected the AAV vector bearing this configuration under the control of the CaMKIIα promoter into mouse frontal cortex (Supplementary Fig. 11a ). We verified that the AAV-CaMKIIα:: Flag-dn-IκBα-p2A-eYFP construct (AAV-dn-IκBα-eYFP) enabled robust and selective overexpression of two proteins from a single open reading frame (Supplementary Fig. 11b,c; see also Supplementary   Fig. 11d ,e for expression of eYFP in CaMKIIα + but not PV + cortical cells and Supplementary Fig. 11f ,g for additional validation of the p2A peptide-linked multicistronic vector in vitro).
Injection of AAV-dn-IκBα-eYFP, but not AAV-eYFP, impeded the effects of chronic clozapine treatment on nuclear translocation of NF-κB into the nucleus of eYFP + cortical neurons (Fig. 6a,c) , validating the capability of this virally mediated gene transfer approach to inhibit NF-κB function. Notably, AAV-mediated overexpression of dn-IκBα-eYFP, but not eYFP alone, prevented upregulation of frontal cortex CaMKIIα + pyramidal HDAC2 expression (Fig. 6b,d ) and deficits in the novel-object recognition test (Fig. 6e) after chronic clozapine treatment (see also Supplementary Fig. 11h ,i for effects of dn-IκBα on p65-dependent activation of Hdac2 promoter activity in HEK293 cells). These results indicate that manipulation of IκBα function in cortical pyramidal neurons affects the impact of chronic atypical antipsychotic drug treatment on Hdac2 promoter activity and HDAC2-dependent cognitive deficits. in the frontal cortex of schizophrenic subjects who were treated with atypical antipsychotic drugs. Postmortem human nuclei were separated by sucrose gradient centrifugation, after which density of NF-κB (p65) was assessed by immunocytochemical staining with antibodies against p65 and the neuronal marker NeuN. Representative immunocytochemical images in frontal cortex nuclei of untreated schizophrenic subjects and individually matched controls (f, top) and in frontal cortex nuclei of atypical antipsychotic-treated schizophrenic subjects and individually matched controls (f, bottom). NF-κB (p65) immunoreactivity levels in neuronal (NeuN + , g) and non-neuronal (NeuN -, h) nuclei. (i,j) Western blots showed upregulation of p65 protein in nuclear preparations from the frontal cortex of atypical antipsychotic-treated schizophrenic subjects as compared to individually matched controls but not in the frontal cortex of untreated schizophrenic subjects as compared to individually matched controls. Representative immunoblots are shown (j). Mean ± s.e.m. *P < 0.05; ***P < 0.001; n.s., not significant. Two-tailed unpaired t test (c: P = 0.47, t 45 = 0.72; d: P = 0.03, t 8 = 2.45). Two-tailed paired t test (g: control versus untreated schizophrenics: P = 0.44, t 9 = 0.80, control versus treated schizophrenics: P = 0.01, t 9 = 2.89; h: control versus untreated schizophrenics: P = 0.27, t 9 = 1.16, control versus treated schizophrenics: P = 0.24, t 9 = 1.25; i: control versus untreated schizophrenics: P = 0.18, t 9 = 1.14, control versus treated schizophrenics: P = 0.04, t 9 = 2.31). Two-way ANOVA with Bonferroni's post hoc test (b: P < 0.001, F 1, 136 = 11.99). Nuclei were stained in blue with DAPI (a,f). Scale bars, 20 µm (a,f). Box plots present, in ascending order, minimum sample value, first quartile, median, third quartile and maximum sample value (g-i).
a r t I C l e S
We next reasoned that repression of frontal cortex NF-κB function by pharmacological or genetic tools would prevent the effects of chronic clozapine treatment on HDAC2 expression and cognitive capabilities. To test this possibility, we first directly compared the effects of the NF-κB inhibitor JSH-23, administered continuously via intracerebroventricular delivery, with those of chronic clozapine treatment. As above (Fig. 1a,d,f) , chronic clozapine treatment induced upregulation of frontal cortex HDAC2 (Fig. 6f,g ) and disrupted novelobject recognition (Fig. 6h) . Notably, adjunctive JSH-23 treatment prevented these effects induced by chronic clozapine (Fig. 6f-h) .
We next aimed to manipulate NF-κB function directly in CaMKIIα + frontal cortex pyramidal neurons. To do so, we used AAV-mediated transgene expression of Cre tagged with the fluorescent construct mCherry under the control of the CaMKIIα promoter. Virally mediated overexpression of Cre in the frontal cortex of p65 loxP/loxP mice induced local and selective knockdown of p65 expression in CaMKIIα + but not PV + neurons (Fig. 6i,j and Supplementary Fig. 11j,k) . Notably, the effects of chronic clozapine treatment on upregulation of frontal cortex HDAC2 expression (Fig. 6k) and deficits in the novel object recognition test (Fig. 6l) were absent in AAV-Cre-injected mice. However, expression of IκBα remained downregulated after chronic clozapine treatment in the frontal cortex of loxP-flanked p65 mice injected with AAV-Cre (Fig. 6k) . This, together with the effect of chronic clozapine treatment on downregulation of IκBα expression in the frontal cortex of Hdac2-cKO mice (Supplementary Fig. 11l,m) , confirms that upstream pathways were responsible for the effects of chronic atypical antipsychotic treatment on IκBα transcription.
Virally mediated activation of frontal cortex NF-kB function decreases synaptic plasticity via HDAC2 To directly evaluate the consequences of long-lasting treatment with antipsychotic medications on NF-κB-dependent transcriptional function in cortical pyramidal neurons, we used AAV vectors to overexpress an HA-tagged constitutively active IκB-kinase (IKK-β-S177E-S181E; HA-caIKK-β) that shows dramatically enhanced kinase activity 42 and consequently models effects of chronic antipsychotic drug treatment on augmentation of NF-κB function. We verified that the AAV-CaMKIIα::HA-caIKK-β-p2A-eYFP construct (AAV-caIKK-β-eYFP) enabled robust and selective overexpression of two proteins from a single open reading frame (Supplementary Fig. 12a-c; see also Supplementary Fig. 12d ,e for additional validation of the p2A peptide-linked multicistronic vector in vitro).
Using this virally mediated overexpression approach, we next interrogated, via injection of AAV-caIKK-β-eYFP or AAV-eYFP, whether long-lasting changes in transcriptional activity of NF-κB are sufficient to affect HDAC2 expression in the frontal cortex of living mice. After 3 weeks of continuous positive modulation of NF-κB-dependent function, we found a significant increase in the translocation of NF-κB into a r t I C l e S the nucleus of eYFP + cortical neurons (Fig. 7a,b) , mimicking the effect of chronic antipsychotic drug treatment in mouse models and in the frontal cortex of schizophrenic subjects treated with atypical antipsychotic drugs (Fig. 4) . Additionally, AAV-mediated augmentation of NF-κB-dependent function induced selective upregulation of HDAC2 immunoreactivity in eYFP + frontal cortex neurons (Fig. 7c,d ), whereas HDAC1 immunoreactivity was unchanged in AAV-caIKK-β-eYFP neurons in comparison with controls ( Supplementary Fig. 12f,g ).
To determine whether such HDAC2 upregulation via NF-κB in frontal cortex regulates synaptic plasticity and behavior, we measured the effect of AAV-caIKK-β-eYFP, or eYFP alone, on cortical synaptic structure, synaptic functional plasticity and animal behavior models of schizophrenia in Hdac2-cKO mice and control littermates. Overexpression of caIKK-β in CaMKIIα + frontal cortex neurons reduced the density of mature mushroom spines but did not change the density of stubby or immature thin spines or total spine density Figure 15 . AAV-Cre was injected into the frontal cortex of p65 loxP/loxP mice. Three weeks after surgery, mice were treated chronically (21 d) with clozapine (10 mg/kg) or vehicle, and expression of Hdac2 and IκBα was assessed by qRT-PCR (n = 6 mice per experimental condition, k). AAV-mediated deletion of frontal cortex p65 in p65 loxP/loxP mice prevents the effects of chronic clozapine treatment on deficits in the novel-object recognition test (n = 6-7 mice per experimental condition, l). Mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant. Two-way ANOVA with Bonferroni's post hoc test (c: P < 0.001, F 1,55 = 13.02; d: P < 0.001, F 1, 269 = 26.82; e: P < 0.002, F 3,82 = 5.23; h: P < 0.03, F 2,36 = 3.56; l: P < 0.001, F 1,22 = 26.33). One-way ANOVA with Bonferroni's post hoc test (f: P < 0.03, F 2,20 = 3.84). Two-tailed unpaired t test (i: P = 0.02, t 4 = 3.62; k: Hdac2: P = 0.65, t 10 = 0.46, IκBα: P = 0.01, t 10 = 2.98). The dashed line indicates chance performance (e,h,l). Nuclei were stained in blue with DAPI (a,b). Scale bars, 20 µm (a,b).
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VOLUME 20 | NUMBER 9 | SEPTEMBER 2017 nature neurOSCIenCe a r t I C l e S (Fig. 7e-i) . Notably, this synaptic remodeling event required HDAC2 function in cortical pyramidal neurons, as the effect of AAV-caIKK-β-eYFP on spine structure was absent in the frontal cortex of Hdac2-cKO mice (Fig. 7e-i) .
Given the effect of NF-κB activity on dendritic spines, we next sought to determine whether NF-κB function also regulates persistent synaptic functional plasticity in frontal neocortical neurons, using a voltage-clamp pairing protocol for inducing long-term potentiation (e-i) AAV-caIKK-β decreases mature structural elements via HDAC2 in frontal cortex. Representative three-dimensional reconstructions of AAV-injected cortical dendritic segments (e). Stubby (f), thin (g), mushroom (h) and total (i) frontal cortex spine density in Hdac2-cKO mice and control littermates after injection of either AAV-HA-caIKK-β or AAV-eYFP (n = 18-27 neurons from 5 or 6 mice per experimental condition). (j,k) AAV-mediated over-expression of HA-caIKK-β blocks LTP in frontal cortical layer II/III neurons via HDAC2. Whole-cell patch-clamp recordings from visually identified eYFP + layer II/III pyramidal neurons were used in conjunction with an LTP-inducing protocol that pairs extracellular stimulation of layer IV with brief depolarization of layer II/III neurons. In control mice (j), LTP was completely blocked in AAV-caIKK-β-eYFP neurons compared to AAV-eYFP neurons (n = 6 neurons from each of 5 mice per experimental condition). In Hdac2-cKO mice (k), LTP in AAV-caIKK-β-eYFP neurons was robust and indistinguishable from that observed in AAV-eYFP neurons (n = 8 neurons from 5 or 6 mice per experimental condition), indicating that the LTP-suppressing effect of AAV-caIKK-β-eYFP required HDAC2. No differences in LTP were observed between AAV-eYFP control (j) and AAV-eYFP or AAV-caIKK-β-eYFP Hdac2-cKO (k) mice (P > 0.05). Mean ± s.e.m. ***P < 0.001; n.s., not significant. Two-tailed unpaired t test (b: P = 0.001,a r t I C l e S (LTP) of local cortical synapses 43 . As described above for spine structure analysis, we overexpressed AAV-caIKK-β-eYFP, or eYFP alone, under the control of the CaMKIIα promoter and then prepared acute coronal slices for whole-cell patch-clamp recordings from visually identified eYFP + layer II/III frontal cortex pyramidal neurons. In control eYFP + neurons, as expected, pairing layer IV stimulation with brief postsynaptic depolarization induced robust LTP in layer II/III neurons that was sustained for 30-45 min, at which time the experiments were terminated (Fig. 7j) . In contrast, no LTP was evident in AAV-caIKK-β-eYFP cortical pyramidal neurons over the same timecourse (Fig. 7j) , indicating that enhanced NF-κB activity suppressed LTP. To probe whether such regulation of LTP by NF-κB required As our data also demonstrate that chronic treatment with atypical antipsychotics reduces the formation of mature spines and impairs cognition through a NF-κB-dependent mechanism involving upregulation of HDAC2, together these observations uncover a previously unsuspected signaling pathway responsible for deleterious effects of these drug agents in terms of synaptic remodeling and cognitive function, and not for their therapeutic actions.
a r t I C l e S expression of HDAC2, as was the case for mushroom spine density ( Fig. 7e-i) , we injected AAV-caIKK-β-eYFP or AAV-eYFP into the frontal cortex of Hdac2-cKO and control littermates and tested for LTP in layer II/III pyramidal neurons. We found robust LTP in caIKK-β-eYFP + Hdac2-cKO neurons, indistinguishable from that in control cells (Fig. 7k) , indicating that the LTP-suppressing effects of enhanced NF-κB activity require HDAC2.
To confirm unequivocally the role of HDAC2 in phenotypes resulting from changes in frontal cortex NF-κB activity, we tested whether AAV-caIKK-β-eYFP alters behavior models of psychosis and cognitive deficits in Hdac2-cKO mice and controls. In healthy humans, hallucinogenic drugs, such as lysergic acid diethylamide (LSD) and DOI, and dissociative drugs, such as phencyclidine (PCP) and dizocilpine (MK801), evoke psychotic and cognitive symptoms resembling certain aspects of schizophrenia [44] [45] [46] [47] . We found that Hdac2-cKO mice responded less intensely than their control littermates when the animals were exposed to conditions that model psychosis, such as head-twitch behavior induced by the LSD-like drug DOI (Fig. 8a) and hyperlocomotor activity induced by the phencyclidine-like drug MK801 (Fig. 8b,c, Supplementary Fig. 13a,b and Supplementary Table 4 ). These results suggest that Hdac2-cKO mice are less predisposed to behavioral phenotypes that model psychosis. Notably, activation of NF-κB function by AAV-caIKK-β-eYFP in frontal cortex CaMKIIα + pyramidal neurons of control mice exacerbated behavior models of psychosis, such as head-twitch induced by DOI (Fig. 8a) and MK801-dependent locomotor activity (Fig. 8b,c, Supplementary  Fig. 13a,b and Supplementary Table 4) . It also impaired social interaction tasks (Fig. 8d-f ) and led to deficits in cognitive function as defined by the novel-object recognition test (Fig. 8g,h) . However, the same AAV-mediated model of prolonged frontal cortex pyramidal NF-κB function augmentation failed to disrupt either behavior models of psychotic symptoms or social and cognitive processes when these behavioral protocols were tested in mice with deleted HDAC2 expression in CaMKIIα + neurons (Fig. 8a-h and Supplementary  Figs. 13 and 14) . Notably, exploratory preference in the novel-object recognition task as a measure of rodent cognitive ability was positively correlated with frontal cortex mushroom spine density in control mice (Fig. 8i) but not in Hdac2-cKO littermates (Fig. 8j) , which suggests that this phenomenon of cortical pyramidal NF-κB-dependent structural plasticity via HDAC2 dominated behavioral deficits in cognitive-related tasks.
DISCUSSION
Findings in mice suggest that activation of cortical 5-HT 2A receptor signaling evokes psychosis-related behavior 18, 48 . Postmortem brain studies demonstrate increased levels of the 5-HT 2A receptor in the frontal cortex of antipsychotic-free schizophrenic subjects but not in schizophrenic subjects treated with atypical antipsychotics 20, 49 . Here we showed downregulation of cortical 5-HT 2A -receptor density in the frontal cortex of mice chronically treated with atypical antipsychotics but not in mice treated with haloperidol. Together, these findings suggest that a decrease in frontal cortex 5-HT 2A -receptor-dependent signaling may contribute to the mechanisms underlying the beneficial effects of chronic antipsychotic treatment on psychotic symptoms. These results, however, do not exclude the possibility of compensatory pathways that may emerge in response to chronic antipsychotic drug exposure and, ultimately, restrain their therapeutic effects 50 . Our current findings highlight a new mechanism whereby cognitive abilities, including working memory, latent learning and recognition memory, deteriorate upon long-lasting treatment with antipsychotic medications. We demonstrate that chronic treatment with atypical, but not with typical, antipsychotic drugs induces 5-HT 2A -receptor-dependent augmentation of HDAC2 epigenetic function via NF-κB, which ultimately leads to detrimental compensatory events along synaptic remodeling and cognitive processes (Fig. 8k) . Further clinical work will be necessary to test the extent to which adjunctive treatment with pharmacological inhibitors of this pathway improves brain plasticity and cognition in schizophrenia patients.
We also observed clear differences between transcriptional networks regulated by chronic clozapine treatment in control versus Hdac2-cKO mice. Although our data revealed the basic signaling and neural circuit mechanism responsible for upregulation of Hdac2 transcription upon chronic atypical antipsychotic treatment, it will be interesting to expand this analysis in future studies to characterize the function of these transcriptional networks in synaptic plasticity and memory formation.
Collectively, this study indicates that inhibition of the pathway by which the 5-HT 2A receptor augments Hdac2 transcription via NF-κB may serve as a pharmacological approach to improve the currently limited therapeutic range of antipsychotic drug treatment. By extension, our findings emphasize the importance of compensatory pathways as one of the probable mechanisms that counteract positive clinical outcomes of compounds administered chronically.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Plasmid construction. All PCR reactions were performed using Pfu Ultra High Fidelity DNA polymerase (Stratagene) in a Mastercycler Ep Gradient Auto thermal cycler (Eppendorf). All the constructs were confirmed by DNA sequencing. The Hdac2 promoter construct (−481 to +141 bp) subcloned into the XhoI and HindIII sites of pGL4.11 [luc2P] plasmid (Promega) has been described previously 16 . Deletion of the putative NF-κB binding site (−394 to −385) was achieved using the site-directed mutagenesis kit, according to the manufacturer's protocol (Stratagene). The pcDNA3-RelA-cFlag construct (Flag-p65) was obtained from Addgene (plasmid #20012). For the HA-caIKK-β construct, the pCR-HA-IKK-β vector was obtained from Addgene (plasmid #15470), after which mutations S177E and S181E were inserted using the sitedirected mutagenesis kit (Stratagene) according to the manufacturer's instructions. For the pcDNA3.1-Flag-dn-IκBα construct, mouse IκBα cDNA along with the Flag tag was PCR amplified from mouse frontal cortex cDNA using the following primers: 5′-TTTTaagcttAGCATGGACTACAAGGATGACGATGA CAAAtttcagccagctgggcac-3′ and 5′-TTTTtctagaTTAttataatgtcagacgctggcc-3′. The PCR product was then ligated into the HindIII and XbaI sites of the pcDNA3.1 (+) plasmid, after which mutations S32A and S36A were inserted using the site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The AAV-CaMKIIα-eYFP-WPRE vector (AAV-CaMKIIα:: eYFP) was donated by Dr. K. Deisseroth. For the AAV-CaMKIIα::Flag-dn-IκBα-p2A-eYFP construct, Flag-dn-IκBα (see above) was PCR amplified using the following primers: 5′-TTTTaccggtGCCACCATGGACTACAAGGA TGACGATGACAAATTTCAG-3′ and 5′-TTTTggcgcgccGTCACAGGCCTG CTCCAGGCTACAC-3′. The PCR product was digested and inserted into the AgeI and AscI sites of the AAV-CaMKIIα-hChR2-(T159C)-p2A-eYFP-WPRE construct (donation of Dr. K. Deisseroth). For the AAV-CaMKIIα::HA-caIKK-β-p2A-eYFP construct, HA-caIKK-β (see above) was PCR amplified using the following primers: 5′-TTTTaccggtGCCACCATGGCTTACCCATACGATG TTCCAGAT-3′ and 5′-TTTTggcgcgccTAATGTCAGACGCTGGCCTCC-3′. The PCR product was digested and inserted into the AgeI and AscI sites of the AAV-CaMKIIα-hChR2-(T159C)-p2A-eYFP-WPRE construct (see above). For the pETDuet-His-TEV-p65-p50 construct, p65 cDNA (residues 19-291; Supplementary Fig. 6b ) along with the TEV protease site was PCR amplified from the Flag-p65 primers described above using the primers 5′-TTTgaatt cGAGAACCTTTATTTCCAAGGCCCTTATGTGGAGATCATCGA-3′ and 5′-TTTAAGCTTTCAGTCTGGCAAGTACTGGAACT-3′. The PCR product was then ligated into the EcoRI and HindIII sites of the pETDuet plasmid, after which p50 cDNA (residues 39-350; Supplementary Fig. 6b ) was PCR amplified from pcDNA3 p50 cFlag obtained from Addgene (plasmid #20018) using the primers 5′-AAAAAAcatatgGGCCCATACCTTCAAATATTAGAG C-3′ and 5′-TTTTTTctcgagTTATTCAGGGTAGTAGAGAAAGGGTTTC-3′. The PCR product was then ligated into the NdeI and XhoI sites of the pETDuet plasmid. Generation and subcloning of the human 5-HT 2A receptor N-terminally tagged with the c-Myc epitope and C-terminally tagged with enhanced cyan fluorescent protein (eCFP) construct has been described previously 20 Luciferase reporter assay. Promoter luciferase reporter assays were carried out as previously described, with minor modifications 16, 17 . Briefly, HEK293 cells were plated at a density of 1-5 × 10 5 in six-well dishes, cultured for 24 h and transfected with the corresponding plasmids. and/or the pcDNA3.1-Flag-dn-IκBα (1.0 µg) or pcDNA3.1. In all assays, cells were transfected with a construct encoding a constitutively active IκB-kinase (IKK-β-S177E-S181E; 0.5 µg). Transfected cells were incubated for 24 h, and the luciferase activity was measured with a luminometer (LMax II 384 Luminescence microplate reader, Molecular Devices) using the Dual-Luciferase reporter assay system (Promega) according to the manufacturer's instructions. Transfection efficiency was normalized with co-expressed pGL4.75 [hRluc/CMV] (Promega) (0.02 µg).
Expression and purification of NF-κB (p65/p50) heterodimer. DNA sequences coding for Rel homology regions (RHR) of p50 (residues 39-350) and p65 (residues 19-291) were subcloned into the pET-DUET1 expression vector (see above). The plasmid was transformed into Escherichia coli BL21(DE3)pLysS cells and grown at 37 °C. The cells were induced with 0.5 mM IPTG and harvested after 4 h. After sonication, the cell lysate was purified on a Ni-NTA column. The heterodimer was further purified using a MonoS 5/5 column and the final purification step used a Superdex-75 gel filtration column in the buffer 25 mM HEPES (pH 7.5), 100 mM NaCl and 1 mM TCEP.
Fluorescence anisotropy DNA binding assay. Fluorescence anisotropy DNA binding assays were carried out as previously reported, with minor modifications 52 . Briefly, binding assays were performed using 5 nM fluorescein labeled 19-mer DNA sites. The two sites, PRDII from the IFNB1 promoter with the sequence 5′-TTAGTGGGAAATTCCTCT-3′ (see ref. 52) and Hdac2 with the sequence 5′-TTCCTCGGGGTCCCCGCGG-3′ (Fig. 3a) , were mixed with the NF-κB p50-p65 heterodimer at different concentrations to a final volume of 300 µL. The reaction buffer was 25 mM HEPES (pH 7.5), 50 mM NaCl and 1 mM TCEP. Fluorescence readings were taken on a PC1 fluorimeter (ISS, Inc.) with excitation and emission filters set at 492 nm and 545 nm, respectively. Before measurement, the DNA/protein mixtures were equilibrated at 20 °C for 20 min.
Anisotropy is calculated as the ratio of the difference between vertical and horizontal emission intensities over the total normalized intensity. Each anisotropy point is the average of 10 measurements. The fraction of DNA bound (B) was calculated using: 18, 31 . For experiments involving 5HT2A-KO mice, wild-type littermates on a 129S6/Sv background were used as controls. All subjects were offspring of heterozygote breeding.
Hdac2 knockout (KO) mice were obtained from The Jackson Laboratory (stock number: 022625). Heterozygous Hdac2 +/− mice were intercrossed to generate Hdac2 −/− mice on a C57BL/6 background. Homozygosity of the Hdac2-null allele resulted in either embryonic lethality or partial lethality during the first few days postnatal as a result of proliferation defects and impaired development (data not shown). These findings are consistent with some 26, 55 but not all 15 of the prior descriptions of global Hdac2 gene deletion. Based on this, we therefore used CaMKIIα-Cre transgenic mice on a C57BL/6 background, in which Cre recombinase is efficiently expressed 56 in combination with conditional loss of function of Hdac2 alleles 26 . In mice, CaMKIIα is expressed postnatally in forebrain glutamatergic pyramidal neurons, beginning 10-14 d after birth 55 . To delete HDAC2 function specifically in forebrain glutamatergic pyramidal neurons, we bred homozygous Hdac2 loxP/loxP mice to the CaMKIIα-Cre transgenic line. In contrast to the global deletion of HDAC2, Hdac2 loxP/loxP :CaMKIIα-Cre (Hdac2-cKO) mice were viable and did not display any gross histological or developmental abnormality (data not shown). Hdac2 loxP/loxP :CaMKIIα-Cre mice were born at near expected Mendelian ratios (data not shown).
p65 loxP/loxP (Rela fl ) mice were obtained from The Jackson Laboratory (Stock number: 024342). Heterozygous p65 loxP/+ mice were intercrossed to generate p65 loxP/loxP mice on a C57BL/6 background.
Genomic DNA was isolated from tails for genotyping by PCR analysis. The primer sequences used were as follows:
5HT2A: forward-1 (5′-CTGTGGGATTTTCTTTCTGCTT-3′), forward-2 (5′-GTGTGATGGCTCTTGATTATGC-3′), common reverse (5′-TCTCTTGAT TCCCACTTTGTGGTT-3′);
Hdac2 loxP/loxP : Hdac2 wt allele forward (5′-GCACAGGCTACTACTGT GTAGTCC-3′), Hdac2 loxP mutant allele: forward (5′-GTCCCTCGA CCTGCAGGAATTC-3′), Hdac2 loxP mutant allele reverse (5′-CCACCAC TGACATGTACCCAAC-3′);
CaMKII-Cre, transgene forward (5′-GCGGTCTGGCAGTAAAAACTATC-3′), transgene reverse (5′-GTGAAACAGCATTGCTGTCACTT-3′); internal positive control forward (5′-CTAGGCCACAGAATTGAAAGATCT-3′), internal positive control reverse (5′-GTAGGTGGAAATTCTAGCATCATCC-3′); and p65 loxP/loxP mutant forward (5′-GCTACTTCCATTTGTCACGTCC-3′), p65 loxP/loxP wt forward (5′-GGGTACGGGTGAATCTTGACT-3′), p65 loxP/loxP common reverse (5′-TGAGGATGGATGGTCCAACT-3′).
Mouse brain samples.
The day of the experiment, mice were killed for analysis by cervical dislocation, and bilateral frontal cortex (bregma 1.90 to 1.40 mm) was dissected and either frozen at −80 °C or immediately processed for RNA extraction, chromatin immunoprecipitation and/or biochemical assays.
The coordinates were taken according to a published atlas of the C57BL/6 and 129/Sv mouse brains 57 .
[ 19 . Nonspecific binding was determined in the presence of 10 µM methysergide. Membrane preparations were incubated at 37 °C for 60 min. Free ligand was separated from bound ligand by rapid filtration (MicroBeta filtermat-96, PerkinElmer) under vacuum through GF/C glass fiber filters. The filters were then rinsed twice with 3 mL of ice-cold incubation buffer, air-dried and counted for radioactivity by liquid scintillation spectrometry using a MicroBeta-2 counter (PerkinElmer).
RNA-seq and differential analysis. RNA was purified from bilateral frontal cortex tissue samples (see above) using RNeasy mini kit (Qiagen). Total RNA (5 µg) was used for mRNA library construction following instructions of Illumina RNA sample kit. All libraries were sequenced on an Illumina HiSeq 2500 platform at Genewiz Inc. (South Plainfield, NJ). Samples were quality control analyzed on an Agilient Bioanalyzer. The library was sequenced with 2 × 100 reads, and the reads were aligned with the STAR v2.5.1b 58 (mouse genome GRCm38 assembly) and Gencode gene annotation (Release M8, Ensembl 83) 59 .The matrix counts of gene expression for all samples were computed by featureCounts v1.5.0-p1 (ref. 60) . Differentially expressed genes (5% FDR and at least 0.2 log 2 fold change) were identified through pairwise comparison using the Bioconductor 46 package DESeq2 v1. 12.4 (refs. 61,62) . Values of scaled gene expression were displayed in the heat map. The RNA-seq data discussed in this paper have been deposited in NCBI's Gene Expression Omnibus (GEO) under the GEO series accession number GSE93918. The gene enrichment analysis was performed with Homer v4. 8.3 (ref. 63) . Gene sets were selected from among those that contained at least two genes and gave P values < 0.05 for the enrichment.
Quantitative real-time PCR. Quantitative real-time PCR (qRT-PCR) assays were carried out in quadruplicate as previously described 18,20,31,64,65 using a QuantStudio 6 Flex Real-Time PCR System (ThermoFisher Scientific; see Supplementary Table 5 for primer pair sequences). For the effect of DOI administration (i.p.) on induction of IκBα mRNA expression in mouse frontal cortex, experiments were performed as previously reported 18, 27 . For the effect of 5-HTP administration (i.p.) on induction of IκBα mRNA expression in mouse frontal cortex, mice received injections (i.p.) of benserazide (30 mg/kg) 66 30 min before 5-HTP or vehicle.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation (ChIP) experiments were performed as previously reported 16, 17 . See Supplementary Table 6 for primer pair sequences.
Postmortem human brain tissue samples. Human brains were obtained at autopsies performed in the Basque Institute of Legal Medicine, Bilbao, Spain. The study was developed in compliance with policies of research and ethical review boards for postmortem brain studies (Basque Institute of Legal Medicine, Spain). We conducted retrospective searches on autopsied humans for previous medical diagnosis and treatment using examiners' information and records of hospitals and mental health centers. After searching antemortem information, 20 subjects who had met criteria of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 67 were selected. Toxicological screening for antipsychotics, other drugs and ethanol was performed in blood, urine, liver and gastric contents samples. All subjects who were drug-free before death (as revealed by the absence of prescriptions in medical histories) also gave negative results in the toxicological screening. The toxicological assays were performed at the National Institute of Toxicology, Madrid, Spain, using a variety of standard procedures including radioimmunoassay, enzymatic immunoassay, high-performance liquid chromatography and gas chromatography-mass spectrometry. Controls for the present study were chosen among the collected brains on the basis, whenever possible, of the following cumulative criteria: (i) negative medical information on the presence of neuropsychiatric disorders or drug abuse; (ii) appropriate gender, age, postmortem delay (time between death and autopsy) and freezing storage time to match each subject in the schizophrenia group; (iii) sudden and unexpected death (motor vehicle accidents); and (iv) toxicological screening for psychotropic drugs with negative results except for ethanol. Specimens of prefrontal cortex (Brodmann area 9) were dissected at autopsy (0.5-1.0 g tissue) on an ice-cooled surface and immediately stored at −80 °C until use. The definitive pairs of antipsychotic-untreated schizophrenics and respective matched controls are shown in Supplementary Table 2, and the definitive pairs of atypical antipsychotic-treated schizophrenics and respective matched controls are shown in Supplementary Table 3 . Pairs of schizophrenic patients and matched controls were processed simultaneously and under the same experimental conditions. Tissue pH is one of the most widely used tissue quality measurements [68] [69] [70] . Tissue pH values were within a relatively narrow range (control subjects: 6.33 ± 0.05; schizophrenic subjects: 6.23 ± 0.07). An algorithm designated as RIN (RNA integrity number) has been recently developed to analyze the quality of the tissue; it assigns a score from 1 to 10 (10 being the best) based on the ribosomal peaks and the extent of RNA degradation products 68, 71 . All brain samples were assayed for RIN values using the Agilent 2100 Bioanalyzer (Applied Biosystems) as previously reported 72 (Supplementary Tables 2 and 3 ).
Nuclei isolation from mouse frontal cortex. Mouse frontal cortex tissue samples (see above) were homogenized using a Teflon-glass grinder (15-20 up-and-down strokes) at 1,500 rpm in 4.8 mL lysis buffer (0.1% Triton X-100, 0.32 M sucrose,JSH-23 or vehicle. The minipump was activated to initiate a continued delivery at 0.11 µL/h over 21 d. The surgical procedure began with an incision over the skull, and the skin was spread apart under the scapulae to create an area for positioning the minipump on the back. Cannulae were permanently fixed to the skull with Loctite skull adhesive (Henkel). Cannulae, tubing and minipumps were all secured under the skin using Vetbond tissue adhesive (3M) and two staples.
Head-twitch behavioral response. Behavioral testing took place between 9:00 a.m. and 6:00 p.m. Head-twitch behavioral assay was performed, as previously described 16 .
Locomotor activity. Motor function (locomotor activity) was assessed using a computerized three-dimensional activity monitoring system, as previously reported 16 .
Social interaction test.
Mice were individually housed in a homecage for 2 d before the trial. In the first 5-min trial, an age-matched intruder mouse was introduced into the resident's home cage under bright light conditions. Behavior was recorded on video for blind scoring. The duration of social interactions (close following, inspection, anogenital sniffing and other social body contacts, except aggressive behavior), aggression (attacking/biting and tail rattling) and escape behaviors were scored. Four trials, with an intertrial interval of 30 min, were used to analyze social behavior, using the same intruder mouse. Intruder mice had been selected based on their lack of aggressive behavior.
Novel-object recognition (NOR) test.
Mice were habituated for 10 min to the NOR arena for three consecutive days before the first NOR test. On the days of testing, mice were given a 10-min acquisition trial and a 5-min recognition trial, separated by a 24 h intertrial return to their home cage. During the acquisition trial, the animals were allowed to explore two different objects (A and B). During the recognition trial, the animals explored a familiar object (A) from the acquisition trial and a novel object (C). Behavior was recorded on video for blind scoring of object exploration. Object exploration was defined as the animal licking, sniffing or touching the object with the forepaws while sniffing. The exploration time of each object (in s) was recorded manually by the use of two stopwatches. The exploratory preference (100 × (time spent exploring the novel object/total exploration time)) was then calculated for retention trials. If the exploration time in the acquisition or retention trials to either object was < 5 s, the data were excluded from analysis. This rarely occurred and did not affect our ability to complete the analysis using the data from the remaining animals of that group.
Spontaneous alternation behavior in a Y-maze test. Spontaneous alternation behavior comprised the tendency for mice to alternate their (conventionally) nonreinforced choices of Y-maze arms on successive opportunities 79 . Each arm or the Y-maze was 40 cm long, 12 cm high, 3 cm wide at the bottom and 10 cm wide at the top. The arms converge in an equilateral triangular central area that is 4 cm at its longest axis. Each mouse was placed individually at the center of the apparatus and allowed to move freely through the maze during an 8-min session. The number of arm entries was recorded visually. Alternation was defined as successive entries into the three arms on overlapping triplet sets. The alternation was calculated as the ratio of actual to possible alternations (defined as the total number of arm entries minus 2) multiplied by 100. Spontaneous alternation (%), defined as successive entries into the three arms on overlapping triplet sets, is associated with spatial short-term memory.
Latent learning in the water-finding test. The apparatus consisted of an open field (30 × 50 × 15 cm high) with an alcove (10 × 10 × 10 cm) in the middle of one of the long walls of the enclosure. The floor of the open field was divided into 15 identical squares for measuring locomotor activity. A drinking tube, identical to those used in the home cages, was inserted into the center of the alcove ceiling with its tip 6.5 cm (in the training trial) or 7.5 cm (in the test trial) above the floor. The test consisted of two trials: a training trial (the first day) and test trial (the second day). In the training trial, mice not deprived of water were placed individually into one corner of the open field of the apparatus. Each mouse was allowed 3 min to explore the environment; the 3 min was counted from the time the mouse started to explore. During this time, ambulation was measured by counting the number of times the animals crossed from one square to another in the open field. The frequency of touching, sniffing or licking of the water tube in the alcove (number of approaches) was also recorded. Animals that did not start exploring after 3 min had elapsed or that did not find the drinking tube during the 3 min exploratory period were omitted from the test trial. The mice were immediately returned to their home cages after the training trial. The mice were deprived of water for 24 h before the test trial. In the test trial, mice were again individually placed on the test apparatus 24 h after the single test trial. The time until the mouse moved out of the corner was measured as the starting latency. In addition, the time taken to enter the alcove (entering latency) and the time between entering the alcove and drinking the water (finding latency) were scored. Thus, the drinking latency consisted of the sum of the entering and finding latencies.
Statistical analysis. Statistical analyses were performed with GraphPad Prism software version 6. For all ChIP and mRNA data, fold changes relative to controls were determined using the corrected C t method 16, 31 . In immunoblot assays in postmortem human brain, the theoretical amount of protein in each sample was obtained by interpolation of the integrated optical density in the standard curve and compared with the real amount of protein loaded into the gel well 74, 80 . Immunohistochemical images were acquires using confocal fluorescence microscope (see above) at identical settings for each of the conditions. Images were quantified using NIH Image 1.62 by an experimenter blind to treatment, viral injection and/or genotype groups. For quantifying HDAC1 or HDAC2 immunoreactivity in mouse tissue sections, the mean signal intensities of HDAC1 or HDAC2 were measured in CaMKIIα + , PV + or eYFP + cells. For quantifying synaptophysin immunoreactivity after chronic clozapine treatment, the mean signal intensity of synaptophysin immunoreactivity in the different layers of the frontal cortex and regions of the hippocampus (DAPI) was measured in both hemispheres of treated mice and controls. For the quantification of synaptophysin immunoreactivity in stereotaxically injected mice, the mean signal intensity of synaptophysin immunoreactivity was measured in the different layers of the frontal cortex (DAPI) in the stereotaxically injected site (eYFP + neuronal bodies) and the contralateral (mock-injected) hemisphere. For calculating p65 subcellular localization (nuclear/cytoplasmic), the mean signal intensity of nuclear p65 (i.e., p65 signal overlapping the DAPIstained area) was divided by the mean signal intensity of cytoplasmic p65 (i.e., CaMKIIα + or eYFP + area not overlapping with DAPI-stained area). For quantifying neuronal nuclear p65 in postmortem human brain samples, the mean intensity signal of p65 in NeuN + or NeuN -nuclei was quantified (see also above). Microscope images were taken by an observer who was blind to the experimental conditions. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in our previous publications 16 . Data distribution was assumed to be normal, but this was not formally tested. Animals were randomly allocated into the different experimental groups. Data points were excluded based on previously established criterion and were set to ± 2 s.d. from the group mean. The statistical significance of experiments involving three or more independent variables on a continuous dependent variable was assessed by three-way ANOVA. The statistical significance of experiments involving three or more groups and two or more treatments was assessed by two-way ANOVA followed by Bonferroni's post hoc test. Statistical significance of experiments involving three or more groups was assessed by one-way ANOVA followed by Bonferroni's post hoc test. Statistical significance of experiments involving two groups was assessed by Student's t test. The effects on mRNA expression of multiple genes or ChIP assays at different regions of a particular gene were assessed by correcting the α value for multiple independent null hypotheses. This was performed by using the Holm's sequentially rejective Bonferroni method as follows: α′ = 1 − (1 − α) (1/N) , where α = 0.05 and N = the number of independent null hypothesis (for example, number of modulated genes) 16, 31, 81 . Correlation analysis was conducted using the Pearson's r. The level of significance was set at P = 0.05. Al values included in the figure legends represent mean ± s.e.m. A Life Sciences Reporting Summary is available.
Data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request. Describe the software used to analyze the data in this study.
Statistical analyses were performed with GraphPad Prism software version 6.
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